Publication | Closed Access

Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the ‘Arbeitsgemeinschaft Internistische Onkologie’

OncologyPancreatic CancerGastrointestinal OncologyMedicineRash-positive PatientsPharmacotherapyMetastatic Pancreatic CancerCancer TreatmentPharmacologyRadiation OncologyMolecular Oncology